This finding suggests that LUC could serve as a practical and accessible biomarker for predicting the risk of severe neutropenia, offering a valuable tool for mitigating one of the most common and impactful side effects of CDK4/6 inhibitor therapy. This evidence concerns the gene CDK4 and neutropenia.